DS-1 (drug)
Systematic (IUPAC) name | |
---|---|
4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide | |
Identifiers | |
CAS Number | 372497-52-4 |
PubChem | CID 979735 |
IUPHAR/BPS | 4183 |
ChemSpider | 849261 |
Chemical data | |
Formula | C18H10Br2ClN3OS |
Molar mass | 511.617 g/mol |
| |
(verify) |
DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]
See also
References
- ↑ Wafford, KA; Van Niel, MB; Ma, QP; Horridge, E; Herd, MB; Peden, DR; Belelli, D; Lambert, JJ (2009). "Novel compounds selectively enhance delta subunit containing GABA a receptors and increase tonic currents in thalamus". Neuropharmacology 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200.
This article is issued from Wikipedia - version of the Monday, December 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.